Core Viewpoint - Shanghai Kasei Biotechnology Co., Ltd. has announced a share repurchase plan proposed by its original controlling shareholder, with a total repurchase amount expected to be between 10 million and 20 million yuan [1] Group 1: Share Repurchase Details - The share repurchase plan was approved by the board of directors on October 21, 2024, and will be implemented from October 21, 2024, to October 20, 2025 [1] - As of September 30, 2025, the company has repurchased a total of 230,366 shares, accounting for 0.0319% of the total share capital [1] - The total amount spent on repurchases so far is 10,497,716.71 yuan, with the actual repurchase price ranging from 44.08 yuan to 53.40 yuan per share [1] Group 2: Future Plans - The company will continue to advance the share repurchase as per regulations and will disclose information in a timely manner [1]

Core Viewpoint - The company, Kaisa Bio, announced its plan to utilize the shareholder meeting reminder service provided by Shanghai Stock Exchange Information Network Co., Ltd. to actively remind shareholders to participate in voting through smart SMS and other means [1] Group 1 - The company will delegate the task of sending meeting invitations and agenda information to each investor to Shanghai Stock Exchange Information [1]

上海凯赛生物技术股份有限公司 2025 年第三次临时股东会会议资料 证券代码：688065 证券简称：凯赛生物 2025 年第三次临时股东会会议资料 中国·上海 二〇二五年十月十五日 上海凯赛生物技术股份有限公司 2025 年第三次临时股东会会议资料 目 录 | 上海凯赛生物技术股份有限公司 | 2025 年第三次临时股东会会议须知 1 | | --- | --- | | 上海凯赛生物技术股份有限公司 | 2025 年第三次临时股东会议程 3 | | 议案一：关于《公司 2025 | 年员工持股计划（草案）》及其摘要的议案 4 | | 议案二：关于《公司 2025 | 年员工持股计划管理办法》的议案 5 | | 议案三：关于授权董事会办理公司 | 2025 年员工持股计划相关事宜的议案 6 | 上海凯赛生物技术股份有限公司 2025 年第三次临时股东会会议资料 上海凯赛生物技术股份有限公司 上海凯赛生物技术股份有限公司 地址：中国（上海）自由贸易试验区蔡伦路 1690 号 5 幢 邮编：201203 电话：86-21-50801916 传真：86-21-50801386 网站：http://www.catha ...

为更好地服务广大中小投资者，确保有投票意愿的中小投资者能够及时参会、 及时投票，公司拟使用上证所信息网络有限公司（以下简称"上证信息"）提供 的股东会提醒服务，委托上证信息通过智能短信等形式，根据股权登记日的股东 名册主动提醒股东参会投票，向每一位投资者主动推送股东会参会邀请、议案情 况等信息。投资者在收到智能短信后，可根据《上市公司股东会网络投票一键通 服务用户使用手册》（下载链接：https://vote.sseinfo.com/i/yjt_help.pdf）的提示 步骤直接投票，如遇拥堵等情况，仍可通过原有的交易系统投票平台和互联网投 票平台进行投票。 若广大投资者对本次服务有任何意见或建议，可通过邮件、投资者热线等方 式向公司反馈，感谢广大投资者对公司的关注与支持。 特此公告。 上海凯赛生物技术股份有限公司 董事会 证券代码：688065 证券简称：凯赛生物 公告编号：2025-056 上海凯赛生物技术股份有限公司 关于股东会开设网络投票提示服务的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海凯赛生物技术股 ...

Group 1 - The company announced that as of the date of the announcement, the total amount of external guarantees provided by its non-wholly-owned subsidiaries is 500 million yuan, all of which are guarantees among non-wholly-owned subsidiaries [1] - For the year 2024, the company's revenue composition is as follows: synthetic biological materials industry accounts for 95.31%, while other businesses account for 4.69% [1] - The current market capitalization of the company is 37.2 billion yuan [2]

Company Overview - Kaisa Biotech (SH 688065) announced on September 29 that its third board meeting was held to discuss the proposal for the postponement of certain fundraising projects [1] - As of the report, Kaisa Biotech has a market capitalization of 37.2 billion yuan [1] Revenue Composition - For the year 2024, Kaisa Biotech's revenue composition is as follows: synthetic biological materials account for 95.31% and other businesses account for 4.69% [1]

Core Viewpoint - 凯赛生物 has announced a draft employee stock ownership plan (ESOP) for 2025, aimed at enhancing talent retention and attracting skilled personnel [1] Group 1: Employee Stock Ownership Plan Details - The ESOP will include up to 155 participants, excluding reserved shares, comprising directors (excluding independent directors), senior management, middle management, and key technical (business) personnel [1] - The total number of shares to be held under the ESOP will not exceed 1.3 million shares, representing approximately 0.18% of the company's total share capital at the time of the announcement [1] - A reserve of 150,000 shares will be set aside, accounting for 11.54% of the total shares in the ESOP [1] Group 2: Stock Purchase Price - The purchase price for the shares from the company's repurchase account will be set at 25.53 yuan per share, including reserved shares [1]

Core Viewpoint - Kaisa Bio (688065.SH) has disclosed a draft employee stock ownership plan for 2025, aimed at enhancing talent retention and attracting skilled personnel [1] Group 1: Employee Stock Ownership Plan Details - The plan includes participation from company directors (excluding independent directors), senior management, middle management, and key technical (business) personnel [1] - The total number of participants in the initial setup of the plan will not exceed 155 individuals, with 6 being directors and senior management [1] - The stock source for the plan will be shares repurchased by the company, specifically from its dedicated repurchase account [1] Group 2: Stock and Financial Details - The number of shares to be held under the employee stock ownership plan will not exceed 1.3 million shares, representing approximately 0.18% of the company's total share capital at the time of the plan's announcement [1] - To support sustainable development and retain talent, the plan reserves 150,000 shares as a reserve, accounting for 11.54% of the total shares in the plan [1] - The purchase price for the shares from the repurchase account is set at 25.53 yuan per share, including the reserved shares [1]

上海凯赛生物技术股份有限公司 2025 年员工持股计划管理办法 上海凯赛生物技术股份有限公司 2025 年员工持股计划管理办法 第一章 总则 第一条 为规范上海凯赛生物技术股份有限公司（以下简称"凯赛生物"或 "公司"）2025 年员工持股计划（以下简称"本员工持股计划"）的实施，根据 《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证 券法》（以下简称"《证券法》"）、《关于上市公司实施员工持股计划试点的 指导意见》（以下简称"《指导意见》"）、《上海证券交易所科创板上市公司自 律监管指引第 1 号——规范运作》（以下简称"《自律监管指引第 1 号》"）等有 关法律、行政法规、规章、规范性文件和《上海凯赛生物技术股份有限公司章程》 （以下简称"《公司章程》"）的规定，特制定《上海凯赛生物技术股份有限公 司 2025 年员工持股计划管理办法》（以下简称"本管理办法"）。 第二章 本员工持股计划的制定 第二条 本员工持股计划的目的 公司依据《公司法》《证券法》《指导意见》《自律监管指引第 1 号》等有 关法律、行政法规、规章、规范性文件和《公司章程》的规定，制定了《上海凯 赛生物技术股份有限 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-051 上海凯赛生物技术股份有限公司 关于非全资控股子公司之间提供担保额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 上海凯赛生物技术股份有限公司（以下简称"凯赛生物"或"公司"）授权公 司非全资控股子公司在其他非全资控股子公司申请信贷业务及日常经营需要时，为 其提供担保。在授权期内，上述担保发生余额合计不超过人民币200,000万元。实际 担保金额以最终签署并执行的担保合同或金融机构批复为准。 ● 拟担保人/拟被担保人：均为公司合并报表内非全资控股子公司，且拟担保人 与拟被担保人的股东及各股东的持股比例均相同。 ● 截至本公告披露之日，公司非全资控股子公司对外担保总额为50,000万元， 均为非全资控股子公司之间担保。除上述担保外，公司非全资控股子公司无其他对 外担保，被担保人未提供反担保，无逾期担保，无涉及诉讼的担保。 ● 拟担保人/拟被担保人均为公司控股且股权架构一致，担保风险总体可控，不 存在损害公司及股东利益的情形。 ● ...